Results 71 to 80 of about 8,790,513 (336)

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham, Casey Vanderlip, Colin Birkenbihl, Eashwar Krishna, Chizobam Ugboaja, Andrew E. Budson, Brandon Frank, for the Alzheimer's Disease Neuroimaging Initiative   +7 more
wiley   +1 more source

On Projection of Costs and Incremental Cost-Effectiveness Ratios: A Data Example [PDF]

International Journal of Health Sciences (IJHS), 2015
Cost and cost-effectiveness analysis has been more and more important to both policy makers and clinicians in assessing health care delivery. The incremental costeffectiveness ratio (ICER) is widely used inpractice to evaluate the relative health benefit of one treatment over another.
openaire   +1 more source

The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices

Expert Review of Pharmacoeconomics & Outcomes Research, 2022
There is controversy on whether to use incremental monetary net benefit (INMB) or incremental cost-effectiveness ratio (ICER) in health economic evaluations alongside randomized controlled trials. We studied the impact of restricted mean survival time (RMST) on the long-term projection of INMB and ICER.
Fei Yuan, Shrikant I. Bangdiwala, Wesley Tong, Andre Lamy   +3 more
openaire   +2 more sources

Pharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS)

Cost Effectiveness and Resource Allocation
Background Treatment cost and high prevalence of Poly Cystic Ovarian Syndrome (PCOS) is a very challenging issue globally. Due to this reason; current study was conducted to determine pharmaco-economy of conventional and non-conventional treatments for ...
Darakhshan Masroor, Sheikh Abdul Khaliq, Syed Muzzammil Ahmad, Farah Mazhar, Iqbal Azhar   +4 more
doaj   +1 more source

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

Arthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos, José Miguel Sequí‐Sabater, Diego Benavent   +2 more
wiley   +1 more source

Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease

Frontiers in Medicine
BackgroundGaucher disease (GD) is an autosomal recessive disorder with a wide range of clinical symptoms that cause abnormal function of parenchymal organs such as liver and spleen in patients.
Yueyang Huang, Hongmei Yuan, Zhe Huang
doaj   +1 more source

Model Outcomes and Incremental Cost-Effectiveness Ratio Over 20 Years.

, 2015
CI = confidence interval; CVD = cardiovascular; SD = standard deviation;Model Outcomes and Incremental Cost-Effectiveness Ratio Over 20 Years.
Joshua Byrnes (835387), Paul A. Scuffham (386394), Christine Pollicino (835390), Yih-Kai Chan (835389), Melinda Carrington (835388), Natalie Dubrowin (835391), Simon Stewart (386388)   +6 more
core   +1 more source

Race and Household Income Are Associated With Disease Outcomes in Pediatric Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Hospitalized in the United States

Arthritis Care &Research, EarlyView.
Objective Race and household income impact outcomes in patients with rheumatic conditions; however, their role in pediatric antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) remains poorly understood. We aimed to evaluate whether race and ethnicity and household income are associated with severe AAV disease and renal outcomes among
Roberto Alejandro Valdovinos, William Daniel Soulsby III, Emily von Scheven   +2 more
wiley   +1 more source

Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer

Gynecologic Oncology Reports
Objective: To review the cost-effectiveness of chemotherapy and immunotherapy-based regimens for advanced and recurrent endometrial cancer, focusing on incremental cost-effectiveness ratios (ICERs).
Katsuaki Inami
doaj   +1 more source

Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer.

Journal of Thoracic Oncology, 2019
INTRODUCTION A multicenter randomized clinical trial in France found an overall survival benefit of web-based patient-reported outcome (PRO)-based surveillance after initial treatment for lung cancer compared with conventional surveillance.
T. Lizée, E. Basch, P. Trémolières, E. Voog, J. Dômont, G. Peyraga, T. Urban, J. Bennouna, A. Septans, Magali Balavoine, B. Detournay, F. Denis   +11 more
semanticscholar   +1 more source